When private equity firms and strategic acquirers evaluate life sciences companies, they typically focus on market size, intellectual property, and potential for financial performance. Yet one critical factor consistently gets relegated to the back burner: regulatory readiness. Our 25+ years of experience with medtech, pharma, and nutraceutical companies has caused us to witness how regulatory… Read more